Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...

Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Thermo Fisher Scientific agreed to pay about $4.1 billion in cash to acquire Solventum’s purification and filtration business ...